Regeneron Reports IDMC Clearance of Efficacy for REGEN-COV (Casirivimab + Imdevimab) in P-III COVID-19 Outpatient Outcomes Trial
Shots:
- Regeneron reported changes to the P-III study assessing REGEN-COV in non-hospitalized patients with COVID-19- following recommendations from the IDMC
- The IDMC found clear clinical efficacy in reducing the rate of hospitalization and death with both doses (1-200 & 2-400 mg) of REGEN-COV vs PBO. The company will immediately stop enrolling patients in the PBO group- following the IDMC’s recommendation
- The trial will continue to enroll patients in both treatment arms. IDMC has also reassured that REGEN-COV effectively neutralizes emerging strains of the virus in its preclinical data
Ref: Regeneron | Image: The Print
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com